调强放疗同步紫杉醇方案化疗治疗食管鳞癌近期疗效观察

调强放疗同步紫杉醇方案化疗治疗食管鳞癌近期疗效观察

郭俊俊;刘慧娟;王蒨;车宇;吴湘阳

【期刊名称】《现代肿瘤医学》

【年(卷),期】2014(000)009

【摘要】目的：观察调强放疗同步紫杉醇＋顺铂方案化疗治疗食管鳞癌的近期疗

效及治疗相关不良反应。方法：我院2010年6月-2013年7月收治的70例初治食管鳞癌患者，分为放化疗组36例和单放组34例。单放组：放疗剂量为DT （60-66）Gy/（30-32）f；放化疗组：放疗开始给予紫杉醇135mg/m2，第1天，顺铂25 mg/m2，第1-3天，21天为一个周期，共两个周期。放疗结束后3个月复查食管钡餐片及CT进行疗效评价。结果：放化疗组共36例食管鳞癌患者，治疗结束后3个月总有效率（response rate，RR）＝（CP＋PR）为91．7％，

其中完全缓解率（complete response，CR）为55．6％、部分缓解率（partial response，PR）为36．1％、无缓解率（non-response，NR）为8．3％，总

有效率高于单放组（73．5％），且差异有统计学意义（P＜0．05）。放化疗组1、2级不良反应发生率高于单放组，有统计学意义（P＜0．05），而3级以上不良

反应及1、2级放射性肺炎两组无差异（P＞0．05）。结论：调强放疗联合紫杉

醇＋顺铂方案同步化疗治疗食管鳞癌近期疗效好，不良反应患者可耐

受。%Objective:To observe the short-term efficacy and adverse reactions

of intensity-modulated radio-therapy and concurrent paclitaxel program chemotherapy for esophageal squamous cell carcinoma.Methods:From June 2010 to July 2013,70 previously untreated patients of esophageal squamous cell carcinoma were divided to two groups randomly:36 patients

were treated by intensity-modulated radiotherapy and concurrent paclitaxel+cisplatin chemotherapy,and 34 patients treated by intensity-modulated radiotherapy only.Radiotherapy only group:Radiation dose were DT (60-66)Gy/(30-32)f;Chemo-radiotherapy group:Chemotherapy started with the radiotherapy,pa-clitaxel 135mg/m2,d1,cisplatin

25mg/m2,d1 -3,21 days a cycle,for two cycles.To evaluate the effect by esophageal barium meal and CT 3 months after the radiotherapy.Results:In 36 patients of chemo-radiotherapy group,the overall response rate was 91.7%(CR+PR),and complete,partial,non-response rates were

55.6%,36.1%,8.3% re-spectively,the overall response rate was higher than radiotherapy group(73.5%),and the difference has statistical significance(P<0.05).The adverse reactions of grade 1,2 in chemo-radiotherapy group were higher than radiother-apy group(P<0.05),but adverse reactions of grade 3 or more and grade 1,2 of radiation-related pneumonitis were no significant difference between two

groups(P>0.05).Conclusion:The short-term efficacy of intensity-modula-ted radiotherapy and concurrent paclitaxel program chemotherapy for esophageal squamous cell carcinoma was better, and the adverse reactions could be tolerated.

【总页数】4页(P2095-2098)

【作者】郭俊俊;刘慧娟;王蒨;车宇;吴湘阳

【作者单位】陕西省肿瘤医院放疗科，陕西西安710061;陕西省肿瘤医院放疗科，陕西西安 710061;陕西省肿瘤医院放疗科，陕西西安 710061;陕西省肿瘤医院放

疗科，陕西西安 710061;陕西省肿瘤医院放疗科，陕西西安 710061

【正文语种】中文

【中图分类】R735.1

【相关文献】

1.调强放疗同步化疗治疗食管癌的近期疗效观察 [J], 王岚

2.调强放疗同步两种方案化疗治疗宫颈癌近期疗效及不良反应对比分析 [J], 唐滟;袁亚维;彭培清;卢灿;王柏耀

3.调强放疗同步PF方案化疗治疗食管癌的近期疗效观察(附30例报道) [J], 叶宏勋;赵莺;张锐;古亮;丁文秀

4.紫杉醇联合顺铂方案同步放化疗治疗中晚期宫颈癌近期疗效观察 [J], 汪志求;韩光锋;段爱雄

5.调强放疗联合LF方案化疗治疗胸上段食管鳞癌近期疗效观察 [J], 张江洲;王志刚;刘艳屏;高霞;吴晶;黄慧;黄娅丽;陶丹;彭毅

因版权原因，仅展示原文概要，查看原文内容请购买